J
Joakim Dillner
Researcher at Karolinska University Hospital
Publications - 631
Citations - 39283
Joakim Dillner is an academic researcher from Karolinska University Hospital. The author has contributed to research in topics: Cervical cancer & Population. The author has an hindex of 91, co-authored 596 publications receiving 35534 citations. Previous affiliations of Joakim Dillner include World Health Organization & Karolinska Institutet.
Papers
More filters
Journal ArticleDOI
Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions
Luisa L. Villa,Gonzalo Perez,Susanne K. Kjaer,Jorma Paavonen,Matti Lehtinen,Nubia Muñoz,Kristjan Sigurdsson,Mauricio Hernández-Ávila,Finn Egil Skjeldestad,Steinar Thoresen,Patricia J. Garcia,Slawomir Majewski,Joakim Dillner,Sven Eric Olsson,Hseon Tay Eng,F. Xavier Bosch,Kevin A. Ault,Darron R. Brown,Daron G. Ferris,Laura A. Koutsky,Robert J. Kurman,Evan R. Myers,Eliav Barr,John W. Boslego,Janine T. Bryan,Mark T. Esser,Christine K. Gause,Teresa M. Hesley,Lisa Lupinacci,Heather L. Sings,Frank J. Taddeo,Annemarie R. Thornton +31 more
TL;DR: In young women who had not been previously infected with HPV-16 or HPV-18, those in the vaccine group had a significantly lower occurrence of high-grade cervical intraepithelial neoplasia related to HPV- 16 or HPV -18 than did those inThe placebo group.
Journal ArticleDOI
Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials
Guglielmo Ronco,Joakim Dillner,K. Miriam Elfström,Sara Tunesi,Peter J.F. Snijders,Marc Arbyn,Henry C Kitchener,Nereo Segnan,Clare Gilham,Paolo Giorgi-Rossi,Johannes Berkhof,Julian Peto,Chris J.L.M. Meijer +12 more
TL;DR: Data of large-scale randomised trials support initiation of HPV-based screening from age 30 years and extension of screening intervals to at least 5 years, and provide 60-70% greater protection against invasive cervical carcinomas compared with cytology.
Journal ArticleDOI
Human Papillomavirus Infection as a Risk Factor for Squamous-Cell Carcinoma of the Head and Neck
Jon Mork,Anne Kveim Lie,Eystein Glattre,G. Hallmans,Egil Jellum,Pentti Koskela,Bjørn Møller,Eero Pukkala,John T. Schiller,Linda Youngman,Matti Lehtinen,Joakim Dillner,Joakim Dillner +12 more
TL;DR: HPV-16 infection may be a risk factor for squamous-cell carcinoma of the head and neck in subjects who were seropositive for HPV-16, and no increased risk was observed for other HPV types.
Journal ArticleDOI
Human Papillomavirus and Papanicolaou Tests to Screen for Cervical Cancer
Pontus Naucler,Walter Ryd,Sven Törnberg,Anders Strand,Göran Wadell,Kristina Elfgren,Thomas Rådberg,Björn Strander,Bo Johansson,Ola Forslund,Bengt-Göran Hansson,Eva Rylander,Joakim Dillner +12 more
TL;DR: The addition of an HPV test to the Pap test to screen women in their mid-30s for cervical cancer reduces the incidence of grade 2 or 3 cervical intraepithelial neoplasia or cancer detected by subsequent screening examinations.
Journal ArticleDOI
Overview of Human Papillomavirus-Based and Other Novel Options for Cervical Cancer Screening in Developed and Developing Countries
Jack Cuzick,Marc Arbyn,Rengaswamy Sankaranarayanan,Vivien Tsu,Guglielmo Ronco,Marie-Hélène Mayrand,Joakim Dillner,Chris J. L. M. Meijer +7 more
TL;DR: The greater sensitivity of HPV DNA testing compared to cytology argues strongly for using HPVDNA testing as the primary screening test in newly implemented programmes, except where resources are extremely limited and only programmes based on visual inspection are affordable.